Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quarfloxin in Low to Intermediate Grade Neuroendocrine Carcinoma
NCT00780663Phase 2Completed
- Sponsor
- Cylene Pharmaceuticals
- Start
- Oct 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of quarfloxin in neuroendocrine carcinoma (NEC), sponsored by Cylene Pharmaceuticals. Started Oct 2008; status: completed.
02
Drugs
quarfloxin
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT00780663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00780663.